ABECMA Strategy
A patient who has received and IMID, proteasome inhibitor and anti-CD38
What is triple class exposed?
450 x 106 CAR+ T Cells
What is the target dose of ABECMA?
ABECMA
What is ide-cel brand name?
or
What is 1st approved MM CAR T?
or
What is the 1st BCMA CAR T
or…
Understanding Referrals
What is phase 1 of CAR T launch?
Deep and Durable Responses
Convenient one-time treatment
CRS and NT Mainly Low-Grade and Resolved Early*
What are the ABECMA key messages?
122
In KarMMa, how many patients had measurable disease at the time of ABECMA infusion?
140
How many patients were enrolled on the KarMMa study?
Establishing Unmet Need
What is phase 2 of CAR T launch?
CAR T believers and CAR T skeptics
What are the 2 HCP types? (Customer segmentation)
1 day
In KarMMa, what is the median time-to-onset of CRS (any grade) following treatment with ABECMA?
19 months
What is the DoR in patients who achieved a CR or better?
4 questions to gain insight on Referrals
What are Key Insightful Questions?
2022
What is the year for expected entry date for Cilta-cel and Blenrep?
2.1 months
What is the median time-to-recovery for patients who experienced grade 3 or 4 thrombocytopenia?
thrombocytopenia
What is the 3rd most common hematologic AE?
or
What is the 4th most common AE (ref: NEJM)
One Focus’ on service the other on on-label data
What differentiate Site Leads and CTSs?
45%
In the Marketing presentation, what was the percentage of triple exposed patients who would be eligible to ABECMA in 4L rrMM?
At least 6 weeks
What is the time period that patients should NOT be vaccinated with live vaccine prior to lymphodepleting chemotherapy?
7
How many patients experienced ≥ grade 3 CRS on KarMMa study (all dose levels) ? (Ref: NEJM)
Less established pathways where 50% of patients come from
What are referrals?